AM also has different oncogenic drivers from cutaneous melanoma, including inconstant KIT mutation rates (3–29%), CCND1 and CDK4 amplification, and deletion or mutations in different genes, such as CDK2NA, PTEN, NF1, and hTERT (2). This evidence concerns the gene CDK4 and cutaneous melanoma.